Scale Management’s Horizon Therapeutics HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q3
$31M Hold
1,710,451
– – 68.19% 1
2016
Q2
$28.2M Hold
1,710,451
– – 66.69% 1
2016
Q1
$28.3M Hold
1,710,451
– – 56.51% 1
2015
Q4
$37.1M Hold
1,710,451
– – 56.74% 1
2015
Q3
$33.9M Hold
1,710,451
– – 42.13% 1
2015
Q2
$59.4M Hold
1,710,451
– – 38.7% 1
2015
Q1
$44.4M Sell
1,710,451
-494,112
-22% -$9.06M 22.19% 2
2014
Q4
$28.4M Buy
+2,204,563
New +$27.6M 16.23% 2

Other funds holding HZNP

Scale Management's HZNP Position: Q3 2016 in Review

Scale Management held its Horizon Therapeutics (HZNP) position steady in Q3 2016 at 1,710,451 shares worth $31M. The position accounts for 68.19% of the portfolio, ranked #1.

Scale Management first reported a position in HZNP in Q4 2014 and has held it in 8 quarters since. The position peaked at $59.4M in Q2 2015. 233 funds tracked by Wall St. Rank hold HZNP as of Q3 2016.

  • Scale Management held 1,710,451 shares of Horizon Therapeutics worth $31M as of Q3 2016.
  • Scale Management left its Horizon Therapeutics share count unchanged in Q3 2016.
  • Horizon Therapeutics made up 68.19% of Scale Management's portfolio in Q3 2016, its #1 holding.
  • Scale Management first reported a position in Horizon Therapeutics in Q4 2014 and has held it in 8 quarters since.
  • Scale Management's Horizon Therapeutics position peaked at $59.4M in Q2 2015.
  • 233 funds tracked by Wall St. Rank held Horizon Therapeutics as of Q3 2016.

Based on Scale Management's 13F filing for Q3 2016, filed 14 Nov 2016.